Anna Brooks on Muck Rack

Anna Brooks

New York
As seen in: diaTribe, Nature, Bandcamp Daily, Everyday Health, Lexington Herald-Leader, Wichita Eagle, Queerty, GBH News (Boston, MA), Bradenton Herald, Belleville News-Democrat, The Herald-Sun (Durham, NC) and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anna

Contact Anna, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Top Diabetes News: ADA 2026

|
By Anna Brooks, Andrew Saintsing, Paul Heltzel
| diaTribe Verified
Diabetes and Weight Management Treatments New Experimental Drug Leads To Dramatic Weight Loss and Relief From Related Conditions GLP-1-based medications have revolutionized blood sugar and weight management, but they aren’t effective for everyone. Eli Lilly, which makes the GLP-1/GIP drug Mounjaro (tirzepatide), is currently developing retatrutide, the first drug to target receptors for three hormones: GLP-1, GIP, and glucagon.
Open in Who Shared Issue with article?

All Eyes on DME: Campaign Spotlights Eye Health and Diabetes

|
By Anna Brooks
| diaTribe Verified
Many people live with diabetic macular edema (DME), a serious eye condition and leading cause of vision loss in people with diabetes. DME is a complication of diabetic retinopathy, another common eye condition in people with diabetes. DME happens when damaged blood vessels in the macula of the eye start to leak, causing symptoms like swelling, blurry vision, dark spots, and, in severe cases, vision loss.
Open in Who Shared Issue with article?

New Oral Drug Foundayo for Weight Loss

|
By Anna Brooks, Charles Alexander
| diaTribe Verified
The latest weight management medication on the market, Eli Lilly’s Foundayo (orforglipron), was approved by the FDA in April 2026. Foundayo is now the second oral GLP-1 medication available for weight management, following the approval of oral Wegovy (semaglutide) in December 2025.
Open in Who Shared Issue with article?
See all 58 licensed articles (90 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified